

MYELOMA TRIALS OPEN TO RECRUITMENT AT THE RLUH

DISEASE	Front Line or Relapsed/Refractory	Key entry criteria	Trial name & Treatment
Myeloma	Front line	Group 1: Newly diagnosed MM, Eligible for ASCT Group 2: Newly diagnosed OR current MM Ineligible for ASCT Group 3: Newly diagnosed OR current SMM	BLOOM = Improving the monitoring and treatment of multiple myeloma patients by comparing cellular and serological markers of minimal residual disease
		Front line treatment or plan agreed to treat with the following within 90 days of consent: IMiDs, proteasome inhibitors or a combination of the 2 or novel therapies	PREAMBLE = observational study ★ For patients requiring front line therapy being treated with IMiDs, proteasome inhibitors or combination novel therapies
	Relapsed /Refractory	At least 1 prior line & in progression. Initiated to or plan agreed to treat with the following within 90 days of consent: IMiDs, proteasome inhibitors or a combination of the 2	PREAMBLE = observational study ★ For patients with relapsed disease or front line therapy being treated with IMiDs, proteasome inhibitors or combination novel therapies
		Determine the role of ixazomib as an Augmented Conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT Consolidation and maintenance strategy in patients with Relapsed multiple myeloma (ACCoRd)	ACCoRD (Myeloma XII) = Phase 3 trial 4-6 cycles ITD to at least SD then randomized to either ASCT-con + Melphalan or ASCT-aug + Melphalan and Ixazomib Maintenance no further treatment or 2 cycles ITD and Ixazomib until DP
		2-4 lines of therapy who are refractory to Lenalidomide in the last line of therapy	OCEAN = Melflufen/Dexamethasone Compared with Pomalidomide/ Dexamethasone
		≥ 2 lines of therapy including proteasome inhibitor and Lenalidomide that Cyclophosphamide and prednisolone would be appropriate	MUK 12 = Phase II randomized trial of Selinexor, Cyclo and Pred v's Cyclo Pred with crossover if required